These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28169120)

  • 21. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 23. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Atkinson L; Elfring GL; Reha A; Miller LL
    Muscle Nerve; 2010 Dec; 42(6):966-74. PubMed ID: 21038378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local dystrophin restoration with antisense oligonucleotide PRO051.
    van Deutekom JC; Janson AA; Ginjaar IB; Frankhuizen WS; Aartsma-Rus A; Bremmer-Bout M; den Dunnen JT; Koop K; van der Kooi AJ; Goemans NM; de Kimpe SJ; Ekhart PF; Venneker EH; Platenburg GJ; Verschuuren JJ; van Ommen GJ
    N Engl J Med; 2007 Dec; 357(26):2677-86. PubMed ID: 18160687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.
    Pane M; Mazzone ES; Sivo S; Sormani MP; Messina S; D'Amico A; Carlesi A; Vita G; Fanelli L; Berardinelli A; Torrente Y; Lanzillotta V; Viggiano E; D Ambrosio P; Cavallaro F; Frosini S; Barp A; Bonfiglio S; Scalise R; De Sanctis R; Rolle E; Graziano A; Magri F; Palermo C; Rossi F; Donati MA; Sacchini M; Arnoldi MT; Baranello G; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E
    PLoS One; 2014; 9(10):e108205. PubMed ID: 25271887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 28. Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information?
    Vill K; Ille L; Schroeder SA; Blaschek A; Müller-Felber W
    Eur J Paediatr Neurol; 2015 Nov; 19(6):640-6. PubMed ID: 26455815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy.
    Tsabari R; Simchovitz E; Lavi E; Eliav O; Avrahami R; Ben-Sasson S; Dor T
    Neuromuscul Disord; 2021 Sep; 31(9):803-813. PubMed ID: 34304968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy.
    Mazzone ES; Pane M; Sormani MP; Scalise R; Berardinelli A; Messina S; Torrente Y; D'Amico A; Doglio L; Viggiano E; D'Ambrosio P; Cavallaro F; Frosini S; Bello L; Bonfiglio S; De Sanctis R; Rolle E; Bianco F; Magri F; Rossi F; Vasco G; Vita G; Motta MC; Donati MA; Sacchini M; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Napolitano S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E
    PLoS One; 2013; 8(1):e52512. PubMed ID: 23326337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
    McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
    Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials.
    Schreiber A; Brochard S; Rippert P; Fontaine-Carbonnel S; Payan C; Poirot I; Hamroun D; Vuillerot C;
    Dev Med Child Neurol; 2018 Feb; 60(2):185-191. PubMed ID: 28990163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.
    Reinig AM; Mirzaei S; Berlau DJ
    Pharmacotherapy; 2017 Apr; 37(4):492-499. PubMed ID: 28152217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy.
    Brehm MA; Kempen JC; van der Kooi AJ; de Groot IJ; van den Bergen JC; Verschuuren JJ; Niks EH; Harlaar J
    PLoS One; 2014; 9(12):e115200. PubMed ID: 25506914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A rebirth for drisapersen in Duchenne muscular dystrophy?
    Hoffman E
    Lancet Neurol; 2014 Oct; 13(10):963-5. PubMed ID: 25209737
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.